Company Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.
Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Country | United States |
Founded | 2018 |
IPO Date | Oct 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 66 |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Contact Details
Address: One Corporate Dr., 2nd Floor South San Francisco, California 94080 United States | |
Phone | (800) 466-6059 |
Website | aligos.com |
Stock Details
Ticker Symbol | ALGS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $15.00 |
CIK Code | 0001799448 |
CUSIP Number | 01626L105 |
ISIN Number | US01626L1052 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Lawrence M. Blatt MBA, Ph.D. | Chief Executive Officer, President and Chairman of the Board |
Dr. Julian A. Symons DPHIL | Executive Vice President and Chief Scientific Officer |
Lesley Ann Calhoun CPA | Executive Vice President and Chief Financial Officer |
Kristina Engeseth | Vice President and Head of People and Culture |
Dr. Matthew W. McClure M.D. | Executive Vice President and Chief Medical Officer |
Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President and Chief Development Officer |
Dr. David B. Smith Ph.D. | Executive Vice President and Head of Chemical Operations |
Dr. Tse-I Lin Ph.D. | Vice President of Early Compound Development and Belgian Site Head |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2024 | 8-K | Current Report |
May 7, 2024 | 10-Q | Quarterly Report |
May 7, 2024 | 8-K | Current Report |
Apr 29, 2024 | ARS | Filing |
Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 12, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 8-K | Current Report |